We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Better Therapeutics, Inc. (NASDAQ: BTTX) (the βCompanyβ) announced today that the Company is terminating its employees and will explore strategic alternatives, including assignment for the...
One million prescriptions for AspyreRx will be offered to patients in underserved communities disproportionately affected by type 2 diabetes Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in...
Company to host sponsored education session on Saturday, March 09, 2024; Expanding access to a high quality and effective lifestyle modification intervention Better Therapeutics, Inc. (NASDAQ:...
Signifies the FDAβs recognition of the Companyβs novel Cognitive Behavioral Therapy as a potential treatment for metabolic dysfunction-associated steatohepatitis Opens an accelerated path towards...
Agreement is an important step towards securing broad coverage Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions